Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

References

• SteeleJCRichardsonJCOlszewskiJProgressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementiaArch Neurol19641033335914107684
   PubMed Web of Science ®Google Scholar
• BensimonGLudolphAAgidYRiluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS studyBrain12009132Pt 115617119029129
   PubMed Web of Science ®Google Scholar
• LudolphACKassubekJLandwehrmeyerBGTauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment optionsEur J Neurol200916329730919364361
   PubMed Web of Science ®Google Scholar
• GolbeLIOhman-StricklandPAA clinical rating scale for progressive supranuclear palsyBrain2007130Pt 61552156517405767
   PubMed Web of Science ®Google Scholar
• LitvanIAgidYCalneDClinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshopNeurology1996471198710059
   PubMed Web of Science ®Google Scholar
• GoetzCGLeurgansSLangAELitvanIProgression of gait, speech and swallowing deficits in progressive supranuclear palsyNeurology200360691792212654953
   PubMed Web of Science ®Google Scholar
• SchragABen-ShlomoYQuinnNPPrevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional studyLancet199935491921771177510577638
   PubMed Web of Science ®Google Scholar
• AlbersDSAugoodSJNew insights into progressive supranuclear palsyTrends Neurosci200124634735311356507
   PubMed Web of Science ®Google Scholar
• BurnDJLeesAJProgressive supranuclear palsyHandb Clin Neurol20078432734918808956
   PubMedGoogle Scholar
• RajputARajputAHProgressive supranuclear palsy: clinical features, pathophysiology and managementDrugs Aging2001181291392511888346
   PubMed Web of Science ®Google Scholar
• LitvanIUpdate on progressive supranuclear palsyCurr Neurol Neurosci Rep20044429630215217544
   PubMedGoogle Scholar
• LangAETreatment of progressive supranuclear palsy and corticobasal degenerationMov Disord200520Suppl 12S839116092096
   PubMed Web of Science ®Google Scholar
• StamelouMReussAPilatusUShort-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trialMov Disord200823794294918464278
   PubMed Web of Science ®Google Scholar
• Westat A pilot trial of lithium in subjects with progressive supranuclear palsy or corticobasal degenerationClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2008 [updated June 18, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00703677. NLM identifier: NCT00703677Accessed January 18, 2012
   Google Scholar
• Ludwig-Maximilians - University of Munich Efficacy, Tolerability and Safety of Azilect in Subjects with Progressive Supranuclear Palsy (PROSPERA)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated August 23, 2010]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01187888. NLM identifier: NCT01187888Accessed January 18, 2012
   Google Scholar
• Nantes University Hospital Trial of valproic acid in patients with progressive supranuclear palsy (depakine)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2006 [updated May 10, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00385710. NLM identifier: NCT00385710Accessed January 18, 2012
   Google Scholar
• BassanMZamostianoRDavidsonAComplete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptideJ Neurochem19997231283129310037502
   PubMed Web of Science ®Google Scholar
• PinhasovAMandelSTorchinskyAActivity-dependent neuroprotective protein: a novel gene essential for brain formationBrain Res Dev Brain Res200314418390
   PubMedGoogle Scholar
• MandelSGozesIActivity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complexJ Biol Chem200728247344483445617878164
   PubMed Web of Science ®Google Scholar
• MandelSRechaviGGozesIActivity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesisDev Biol2007303281482417222401
   PubMed Web of Science ®Google Scholar
• GozesIMorimotoBHTiongJNAP: research and development of a peptide derived from activity dependent neuroprotective protein (ADNP)CNS Drug Rev2005114363378
   Google Scholar
• GozesIStewartAMorimotoBFoxASutherlandKSchmecheDAddressing Alzheimer’s disease tangles: from NAP to AL-108Curr Alzheimer Res20096545546019874271
   PubMed Web of Science ®Google Scholar
• GozesITau pathology and future therapeuticsCurr Alzheimer Res20107868569620678069
   PubMed Web of Science ®Google Scholar
• GozesINAP (davunetide) provides functional and structural neuroprotectionCurr Pharm Des201117101040104421524250
   PubMed Web of Science ®Google Scholar
• Idan-FeldmanASchirerYPolyzoidouEDavunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat modelNeurobiol Dis201144332733921827858
   PubMed Web of Science ®Google Scholar
• LagrèzeWAPielenASteingartRThe peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitroInvest Ophthalmol Vis Sci200546393393815728550
   PubMed Web of Science ®Google Scholar
• VisochekLSteingartRAVulih-ShultzmanIPolyADP-ribosylation is involved in neurotrophic activityJ Neurosci200525327420742816093393
   PubMed Web of Science ®Google Scholar
• Smith-SwintoskyVLGozesIBrennemanDED’AndreaMRPlata-SalamanCRActivity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical culturesJ Mol Neurosci200525322523815800376
   PubMed Web of Science ®Google Scholar
• DivinskiIHoltser-CochavMVulih-SchultzmanISteingartRAGozesIPeptide neuroprotection through specific interaction with brain tubulinJ Neurochem200698397398416893427
   PubMed Web of Science ®Google Scholar
• GozesISpivak-PohisINeurotrophic effects of the peptide NAP: a novel neuroprotective drug candidateCurr Alzheimer Res20063319719916842095
   PubMedGoogle Scholar
• PascualMGuerriCThe peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanolJ Neurochem2007103255756817623041
   PubMed Web of Science ®Google Scholar
• FlemingSMMulliganCKRichterFA pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusionsMol Cell Neurosci201146359760621193046
   PubMed Web of Science ®Google Scholar
• ShiryaevNJouroukhinYGiladiENAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy modelNeurobiol Dis200934238138819264130
   PubMed Web of Science ®Google Scholar
• MorimotoBHDe LannoyIFoxAWGozesIStewartADavunetide pharmacokinetics and distribution to brain after intravenous or intranasal administration to ratChimica Oggi-Chemistry Today20092721620
   Google Scholar
• AlimMAHossainMSArimaKTubulin seeds alpha-synuclein fibril formationJ Biol Chem200227732112211711698390
   PubMed Web of Science ®Google Scholar
• LeeHJKhoshaghidehFLeeSLeeSJImpairment of microtubule-dependent trafficking by overexpression of alpha-synucleinEur J Neurosci200624113153316217156376
   PubMed Web of Science ®Google Scholar
• Chevalier-LarsenEHolzbaurELAxonal transport and neurodegenerative diseaseBiochim Biophys Acta2006176211–121094110816730956
   PubMed Web of Science ®Google Scholar
• BaasPWQiangLNeuronal microtubules: when the MAP is the roadblockTrends Cell Biol200515418318715817373
   PubMed Web of Science ®Google Scholar
• ZhangBMaitiAShivelySMicrotubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy modelProc Natl Acad Sci U S A2005102122723115615853
   PubMed Web of Science ®Google Scholar
• MorrisMMaedaSVosselKMuckeLThe many faces of tauNeuron201170341042621555069
   PubMed Web of Science ®Google Scholar
• Merenlender-WagnerAPikmanRGiladiEAndrieuxAGozesINAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse – a microtubule-deficient model of schizophreniaPeptides20103171368137320417241
   PubMed Web of Science ®Google Scholar
• ZemlyakISapolskyRGozesINAP protects against cytochrome c release: inhibition of the initiation of apoptosisEur J Pharmacol20096181–391419619522
   PubMed Web of Science ®Google Scholar
• DivinskiIMittelmanLGozesIA femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxicationJ Biol Chem200427927285312853815123709
   PubMed Web of Science ®Google Scholar
• GozesIDivinskiINAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cellCurr Alzheimer Res20074550750918220512
   PubMed Web of Science ®Google Scholar
• GozesIDivinskiIThe femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protectionJ Alzheimers Dis200466 SupplS374115665412
   PubMed Web of Science ®Google Scholar
• SudoHBaasPWStrategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseasesHum Mol Genet201020476377821118899
   PubMed Web of Science ®Google Scholar
• MatsuokaYGrayAJHirata-FukaeCIntranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stageJ Mol Neurosci200731216517017478890
   PubMed Web of Science ®Google Scholar
• MatsuokaYJouroukhinYGrayAJA neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s diseaseJ Pharmacol Exp Ther2008325114615318199809
   PubMed Web of Science ®Google Scholar
• GozesIShiryaevYPinsahovAGinzburgIRosenmannHProtecting the brain by nasal peptide delivery: from concept to the clinic. AbstractAlzheimers Dement.200622 SupplS73
   Google Scholar
• Vulih-ShultzmanIPinhasovAMandelSActivity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse modelJ Pharmacol Exp Ther2007323243844917720885
   PubMed Web of Science ®Google Scholar
• SokolowskaPPassemardSMokASchwendimannLGozesIGressensPNeuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsyNeuroscience20117315616821073926
   PubMed Web of Science ®Google Scholar
• ChenSCharnessMEEthanol inhibits neuronal differentiation by disrupting activity-dependent neuroprotective protein signalingProc Natl Acad Sci U S A200810550199621996719047645
   PubMed Web of Science ®Google Scholar
• SchmechelDEGerardGVatakisNGA phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairmentAlzheimers Dement.200844 SupplT483
   Google Scholar
• SchmechelDEGerardGVatakisNGImprovement in cognitive function after 12 weeks of intranasal administration with AL-108 in subjects with mild cognitive impairment; results from a phase 2, double-blind, placebo-controlled study to evaluate safety, tolerability, and efficacyPaper presented at: Alzheimer’s Association International Conference on Alzheimer’s Disease2008Chicago, IL
   Google Scholar
• PetersenRCParisiJEDicksonDWNeuropathologic features of amnestic mild cognitive impairmentArch Neurol200663566567216682536
   PubMedGoogle Scholar
• MarkesberyWRSchmittFAKryscioRJDavisDGSmithCDWeksteinDRNeuropathologic substrate of mild cognitive impairmentArch Neurol2006631384616401735
   PubMedGoogle Scholar
• JichaGAParisiJEDicksonDWNeuropathologic outcome of mild cognitive impairment following progression to clinical dementiaArch Neurol200663567468116682537
   PubMedGoogle Scholar
• JavittDCBuchananRWKeefeRSEffect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophreniaSchizophr Res2011Epub Dec12
   Google Scholar
• BancherCLassmannHBudkaHNeurofibrillary tangles in Alzheimer’s disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau anti-genicity is prominent in all types of tanglesActa Neuropathol198774139462444063
   PubMed Web of Science ®Google Scholar
• BirdiSRajputAHFentonMProgressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied casesMov Disord20021761255126412465065
   PubMed Web of Science ®Google Scholar
• KuiperijHBVerbeekMMBorroniBTau forms in CSF as a reliable biomarker for progressive supranuclear palsyNeurology201176161443 author reply 144321502610
   PubMed Web of Science ®Google Scholar
• KvickströmPErikssonBvan WestenDLattJElfgrenCNilssonCSelective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractographyBMC Neurol2011111321269463
   PubMed Web of Science ®Google Scholar
• TosunDDuchesneSRollandYTogaAWVérinMBarillotC3-D analysis of cortical morphometry in differential diagnosis of Parkinson’s plus syndromes: mapping frontal lobe cortical atrophy in progressive supranuclear palsy patientsMed Image Comput Comput Assist Interv.200710Pt 289189918044653
   PubMedGoogle Scholar
• Warmuth-MetzMNaumannMCsotiISolymosiLMeasurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsyArch Neurol20015871076107911448296
   PubMedGoogle Scholar
• RichardsonJCSteeleJOlszewskiJSupranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of “heterogenous system degeneration”Trans Am Neurol Assoc196388252914272249
   PubMedGoogle Scholar
• MaruffPWerthJGiordaniBCaveneyAFFeltnerDSnyderPJA statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolamPsychopharmacology (Berl)2006186171716572266
   PubMed Web of Science ®Google Scholar
• CuboEStebbinsGTGolbeLIApplication of the Unified Parkinson’s Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scaleMov Disord200015227627910752576
   PubMed Web of Science ®Google Scholar
• PayanCAVialletFLandwehrmeyerBGDisease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS – Parkinson Plus ScalePLoS One201168e2229321829612
   PubMed Web of Science ®Google Scholar
• HenslerMPaulSAbrightCLorenzlSProgressive supranuclear palsy: living environment of the patients in GermanyNervenarzt2011822207214 Article in German20669002
   PubMed Web of Science ®Google Scholar
• RickhamPPHuman experimentation. Code of ethics of the World Medical Association. Declaration of HelsinkiBr Med J19642540217714150898
   PubMed Web of Science ®Google Scholar